BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 19949401)

  • 1. Lessons from 60 years of pharmaceutical innovation.
    Munos B
    Nat Rev Drug Discov; 2009 Dec; 8(12):959-68. PubMed ID: 19949401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The right to a trial: Should dying patients have access to experimental drugs?
    Groopman J
    New Yorker; 2006 Dec; ():40-7. PubMed ID: 17176539
    [No Abstract]   [Full Text] [Related]  

  • 3. 2016 in review: FDA approvals of new molecular entities.
    Griesenauer RH; Kinch MS
    Drug Discov Today; 2017 Nov; 22(11):1593-1597. PubMed ID: 28687460
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Pharmaceutical Industry in 2017. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2018 Feb; 23(3):. PubMed ID: 29495494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cancer research in the United States: A critical review of current status and proposal for alternative models.
    Kantarjian HM; Prat F; Steensma DP; Kurzrock R; Stewart DJ; Sekeres MA; Leveque J
    Cancer; 2018 Jul; 124(14):2881-2889. PubMed ID: 29757456
    [No Abstract]   [Full Text] [Related]  

  • 6. The Pharmaceutical Industry in 2019. An Analysis of FDA Drug Approvals from the Perspective of Molecules.
    de la Torre BG; Albericio F
    Molecules; 2020 Feb; 25(3):. PubMed ID: 32050446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A forensic analysis of drug targets from 2000 through 2012.
    Munos B
    Clin Pharmacol Ther; 2013 Sep; 94(3):407-11. PubMed ID: 23756372
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug discovery in jeopardy.
    Cuatrecasas P
    J Clin Invest; 2006 Nov; 116(11):2837-42. PubMed ID: 17080187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trends in antimicrobial drug development: implications for the future.
    Spellberg B; Powers JH; Brass EP; Miller LG; Edwards JE
    Clin Infect Dis; 2004 May; 38(9):1279-86. PubMed ID: 15127341
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biopharmaceutical statistics in a pharmaceutical regulated environment: past, present, and future.
    Segreti AC; Leung HM; Koch GG; Davis RL; Mohberg NR; Peace KE
    J Biopharm Stat; 2001 Nov; 11(4):347-72. PubMed ID: 12018784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Data Integrity: History, Issues, and Remediation of Issues.
    Rattan AK
    PDA J Pharm Sci Technol; 2018; 72(2):105-116. PubMed ID: 29158286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2020 in review: FDA approvals of new medicines.
    Kinch MS; Kraft Z; Schwartz T
    Drug Discov Today; 2021 Dec; 26(12):2794-2799. PubMed ID: 34252611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Déjà Vu at the FDA.
    Sharfstein J
    Milbank Q; 2017 Jun; 95(2):245-248. PubMed ID: 28378412
    [No Abstract]   [Full Text] [Related]  

  • 14. The impact of external innovation on new drug approvals: A retrospective analysis.
    Liu X; Thomas CE; Felder CC
    Int J Pharm; 2019 May; 563():273-281. PubMed ID: 30664998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 2018 in review: FDA approvals of new molecular entities.
    Kinch MS; Griesenauer RH
    Drug Discov Today; 2019 Sep; 24(9):1710-1714. PubMed ID: 31158510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 17. The history and contemporary challenges of the US Food and Drug Administration.
    Borchers AT; Hagie F; Keen CL; Gershwin ME
    Clin Ther; 2007 Jan; 29(1):1-16. PubMed ID: 17379043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence: the regulatory career of a pharmaceutical concept.
    Carpenter D; Tobbell DA
    Bull Hist Med; 2011; 85(1):93-131. PubMed ID: 21551918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.
    Skydel JJ; Luxkaranayagam AT; Dhruva SS; Ross JS; Wallach JD
    JAMA Netw Open; 2019 May; 2(5):e193410. PubMed ID: 31074812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pipelines turn to biotech.
    Lawrence S
    Nat Biotechnol; 2007 Dec; 25(12):1342. PubMed ID: 18066015
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 24.